首页 | 本学科首页   官方微博 | 高级检索  
     


A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy
Authors:Nakamura Shingen  Horiuchi Noriaki  Katsura Daisuke  Shichijo Kana  Yoshida Sumiko  Harada Eiji  Matsushita Takaya  Oshima Yasushi  Matsuzaki Yasuyuki  Tamaki Yasutami  Kimura Shigeaki  Takeichi Toshiaki  Fujimoto Hiroshi  Masuda Kazuhiko  Iwasaka Naohito  Shinomiya Sadao
Affiliation:Dept. of Internal Medicine, Health Insurance Naruto Hospital.
Abstract:
We presented the case of a 46-year-old man with no medical or family history but with a history of smoking 3 packs of cigarettes per day for the past 25 years. He was admitted to our hospital due to hemoptysis. Chest computed tomography revealed a tumor of right upper lung and interstitial pneumonia in the surrounding lung parenchyma. He was operated upon and diagnosed with stage IIB pleomorphic carcinoma of the lung with invasion of the chest wall. He underwent three courses of postoperative carboplatin (CBDCA) (area under the curve 5 on day 1, every 3 weeks and paclitaxel(PTX) (200 mg/m(2); day 1, every 3 weeks) combination chemotherapy. No recurrence was observed for a period of 760 days after the operation. According to previous reports, lung pleomorphic carcinoma is aggressive and has a poor prognosis. Further, the significance of chemotherapy in the management of this disease has not been established. Postoperative combination chemotherapy of CBDCA and PTX may result in a good prognosis for this disease.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号